Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTo be eligible for Wegovy in the UK, adults generally need a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes or high cholesterol. A prescriber makes the final call after a full clinical assessment — a BMI figure alone is never the whole picture. Wegovy (semaglutide) is a prescription-only medicine, so eligibility for Wegovy is always confirmed through a consultation with a qualified prescriber, not a tick-box form. If you've been wondering whether you'd qualify, the criteria are more nuanced than a single number on the scale, and understanding them properly can save you a lot of confusion.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people who search for Wegovy eligibility criteria already have a rough sense of where their BMI sits. You might have seen the 30 threshold mentioned online, checked your number and thought: that's me. But arriving at the consultation with the right BMI is the start of the process, not the end of it.
What a prescriber actually reviews is the full clinical picture. Your BMI matters, but so does your medical history, your current medications, any conditions you've been diagnosed with, and whether any of those conditions are on the list of weight-related comorbidities that can shift the qualifying threshold. For anyone with a BMI between 27 and 29.9, demonstrating at least one of those conditions, such as type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea, is what opens the door. The BMI requirements for Wegovy are worth reading in detail if you're close to the 30 boundary.
There's also an ethnic-background adjustment built into UK clinical guidance. For people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds are typically 2.5 kg/m² lower, reflecting the evidence that metabolic risk appears at lower BMI values in these groups. A prescriber familiar with current NICE guidance on semaglutide (TA875) will apply this automatically. If you want to work out where you sit before booking, the BMI calculator for Wegovy is a useful starting point.
A BMI of 27 to 29.9 is classified as overweight rather than obese, and Wegovy's licence specifically covers this range when at least one qualifying health condition is present. This is often the part of the eligibility picture that surprises people, and it means some individuals at a BMI that wouldn't traditionally trigger a weight-management referral may still be appropriate candidates.
The weight-related conditions that count include type 2 diabetes, high blood pressure, high cholesterol or triglycerides (dyslipidaemia), obstructive sleep apnoea and cardiovascular disease. These aren't just boxes to tick: they're the conditions that evidence shows are improved when significant weight loss is achieved alongside treatment. Your prescriber will want to see that the condition is documented, not just self-reported.
It's also worth knowing that eligibility for semaglutide as a weight-management medicine differs from eligibility for Ozempic, which is semaglutide licensed specifically for type 2 diabetes rather than weight loss. Wegovy and Ozempic are not interchangeable for prescribing purposes, even though the active ingredient is the same. Getting clarity on which licence applies to your situation is one of the things a proper consultation resolves.
Reviewing the full Wegovy eligibility criteria before your consultation helps you arrive prepared. That said, a prescriber's role isn't to look for reasons to refuse, it's to make sure treatment is safe and appropriate for you specifically.
Certain circumstances put Wegovy outside what's clinically appropriate, regardless of BMI. Wegovy is not licensed for use during pregnancy, while breastfeeding, or when someone is actively trying to conceive. The MHRA advises using effective contraception while on treatment, and for women using oral contraceptives alongside semaglutide, there isn't the same evidence of reduced pill absorption as exists for tirzepatide, though your prescriber will discuss your contraception situation as part of the assessment.
Wegovy is also not licensed for anyone under 18. A personal or family history of medullary thyroid carcinoma, or a condition called MEN2 (Multiple Endocrine Neoplasia type 2), is a contraindication. Certain gastrointestinal conditions and a history of pancreatitis will also prompt careful clinical review. The NHS medicines page for semaglutide lists the main contraindications clearly if you want to check before speaking to a prescriber.
None of this is meant to be discouraging. It's meant to be honest. A service that doesn't ask these questions properly isn't one you should trust with a prescription medicine. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not automated software. If you'd like to explore whether you're a good candidate, our eligibility guide covers the common scenarios in more detail.
Yes, and this distinction catches a lot of people out. The licensed eligibility criteria (BMI 30+, or 27+ with a qualifying condition) apply to private prescribing. NHS access to Wegovy operates under NICE technology appraisal TA875, which sets stricter conditions: treatment is recommended only within a specialist weight management service, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. Ethnic-background thresholds are adjusted here too. Waiting lists for NHS specialist services are commonly long.
Private prescribing through a regulated online pharmacy follows the licensed criteria rather than the NICE commissioning criteria, which is why the route is accessible to more people, faster. That doesn't mean standards are lower, it means the prescriber's assessment is working from the licensed indication rather than NHS rationing thresholds. For a fuller picture of what Wegovy costs through a private service, the Wegovy pricing page explains what a legitimate private prescription includes.
Pen storage is worth a word here: Wegovy is stored in the fridge (2–8°C), and many people find a consistent spot in the fridge door works well as a visual reminder to keep the weekly routine going. The exact room-temperature storage window is set out in the Patient Information Leaflet that comes with your treatment.
If you're ready to find out whether you qualify, check your eligibility with our prescribers. The consultation is free, and a clinician reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.